• Sarah Hormachea Diabetes Care and Education Retatrutide grey market
    Diabetes Care & Education,  Weight, Obesity & Metabolic Health

    Retatrutide and the Grey Market: Buyer Beware

    This should go without saying, but the internet can be both an incredible resource and an extremely dangerous place for health and wellness information. At a time when obesity rates are soaring, mental and emotional stress are at an all-time high, and access to reputable healthcare can feel nearly impossible, many people are turning online in search of solutions. Unfortunately, that desperation leaves individuals vulnerable to the predatory promises of the wellness industry. The latest example is the buzz around retatrutide; or “Reta,” as it’s trending on TikTok. Like candy offered from the back of a van, it’s tempting, accessible,…

  • Sarah Hormachea Diabetes Care and Education ADA Scientific Sessions: Expanding the Discussion to Include Weight Bias
    Clinician Education & Training,  Weight, Obesity & Metabolic Health

    ADA Scientific Sessions: Expanding the Discussion to Include Weight Bias

    This past weekend, I had the pleasure of attending the American Diabetes Association’s 85th Scientific Sessions in Chicago. It was a phenomenal gathering of researchers, clinicians, scientists, and experts in the field of cardiometabolic health. One of the most compelling shifts I observed was the growing emphasis on obesity care and treatment. The Obesity Association, a new division of the American Diabetes Association, recently published the Standards of Care in Overweight and Obesity to guide respectful, evidence-based treatment. These standards highlight weight stigma and bias as critical issues in clinical practice. To support the launch of the standards, a special…

  • Sarah Hormachea Diabetes Care and Education BMI vs body composition in clinical practice
    Clinician Education & Training

    Goodbye BMI? Why Body Composition Is Gaining Ground in Clinics

    The rise of incretin-based therapies for obesity care, like Wegovy (semaglutide) and Zepbound (tirzepatide), has brought renewed attention to the risk of muscle atrophy that can accompany rapid weight loss. To better assess changes in skeletal muscle mass, clinicians are turning to body composition assessment tools to track progress over time. However, the ability to measure, interpret, and communicate changes in body composition is a skill most clinicians haven’t been formally trained in, leaving many feeling like it’s not a tool they can confidently use. I want to push back against that assumption and offer some basic principles to help…